# US 2010/0063023 A1 · Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063023 A1
- Document ID: US20100063023A1
- Status: Published application
- Kind: A1
- Application number: 12/555,850
- Filed: 2009-09-09
- Published: 2010-03-11
- Earliest claimed: 2008-09-10
- Assignees: Wyeth
- Inventors: Tarek Suhayl Mansour; Aranapakam Mudumbai Venkatesan
- Web page: https://patentgrep.com/patent/US20100063023A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 31/04: Antibacterial agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a β-lactamase antibiotic and a compound of formula I, a process of producing the compound, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

## Claims

### Claim 1

A compound of Formula I:
wherein:
one of A and B denotes hydrogen and the other an 8- to 14-membered fused bicyclic or tricyclic heteroaryl group optionally substituted with nitro, C6-14aryl, -heteroaryl, alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —N—R6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, C1-6alkyl-S—, —SO2N—R6R7, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl where s is 0-2, -alkyl-O—-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N—(C1-6alkyl), and —S(═O)s-heteroaryl where s is 0-2;
R5 is H, C1-6alkyl, C5-6cycloalkyl, or CHR3OCOC1-6alkyl;
R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C6-14aryl, or 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, wherein aryl or heteroaryl can be optionally substituted with 1 or 2 of nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, -alkyl-aryl-O—-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; and
R6 and R7 are independently H, or a group selected from C1-6alkyl, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, alkylaryl, arylalkyl, heteroarylalkyl, C1-6alkylheteroaryl, said group being optionally substituted with nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O-cyano, -halogen, -hydroxy, —NR6R7, —COOH, —COO-alkyl, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl, alkoxyalkyl-, C1-5alkyl-S—, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl, wherein s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkyl-N—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl, where s is 0-2; or R6 and R7 can together with the nitrogen to which they are attached form a 3 to 7 membered saturated ring system optionally having in addition to the nitrogen, one or two heteroatoms selected from N—R1, O, and S(═O)n, where n is 0-2;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein A or B is a bicyclic heteroaryl group of the formula:
wherein:
one of Z1, Z2 and Z3 is a carbon bonded to the remainder of the molecule and the other two are independently selected from CR2, N, O, S, and N—R1;
W1, W2 and W3 are each independently selected from CR4R4, S, SO, SO2, O, N—R1, and C(═O), with the proviso that whenever W2 is S or O it is not adjacent to a W1, W2 or W3 that is also S or O;
t is 1-4;
R1 is H, or is a group selected from C1-6alkyl, C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C3-7cycloalkyl, C2-8alkenyl, C2-6alkynyl, C1-6perfluoroalkyl, —S(═O)2C1-6alkyl or C6-14aryl, —C(═O)heteroaryl, —C(═O)aryl, —C(═O)(C1-6alkyl), —C(═O)C3-6cycloalkyl, —C(═O) mono or bicyclic saturated heterocyclyl, C1-6alkylaryl, (C1-6alkyl)heteroaryl, aryl(C1-6alkyl), heteroaryl(C1-6alkyl), C1-6alkyl mono or bicyclic saturated heterocyclyl, arylalkenyl of 8 to 16 carbon atoms, arylalkyloxyalkyl, (C1-6alkyl )O(C1-6alkyl)-aryl, (C1-6alkyl )O(C1-6alkyl)heteroaryl, aryloxy heteroaryloxyalkyl, aryloxyaryl, aryloxyheteroaryl, alkylaryloxyaryl, alkylaryloxyheteroaryl, alkylaryloxyalkylamines, saturated heterocyclyl carbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, —CONR6R7, and —SO2NR6R7, said group being optionally substituted with nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; provided the atom of R1 which bonds to N is not a carbon that is double or triple bonded to another carbon;
R2 is absent, hydrogen, halogen, cyano, N—R6R7, hydroxy; COOR6, C1-6alkylamino (C1-6alkoxy), alkylenedioxy, C1-6perfluoroalkyl, CONR6R7, guanidino or cyclic guanidino, SO2NR6R7, C1-6alkyl, C2-8alkenyl having 1 to 2 double bonds, C2-6alkynyl having 1 to 2 triple bonds; C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxy, alkylaryloxy alkylamines, aryloxy, heteroaryloxy, alkenyloxy, alkynyloxy, aryloxyalkyl amine, C1-6perfluoroalkyl, S(═O)q—C1-6alkyl, S(═O)q— where q is 0-2, alkylaryl, arylalkyl, C1-6alkylheteroaryl, heteroaryl-C1-6alkyl, C1-6alkyl mono or bicyclic saturated heterocyclyl having 1-3 heteroatoms independently selected from O, N or S, arylalkenyl of 8 to 16 carbon atoms, arylalkyloxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, aryloxyaryl, aryloxyheteroaryl, heteroaryloxyaryl, alkyl aryloxyaryl, alkylaryloxyheteroaryl, aryloxyalkyl, heteroaryloxyalkyl, alkylaryloxyalkylamines, C3-7cycloalkyl, saturated or partially saturated heterocyclyl, said group being optionally substituted with nitro, C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, C1-6alkyl-S—, —SO2N—R6R7, C6-14aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O—- alkylN—R6R7, -alkyl-aryl-O-alkylN—R5R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; provided that the atom of R2 that bonds to N is not a carbon that is double or triple bonded to another carbon;
each R4 is independently H or C1-6alkyl optionally substituted with nitro, C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, C1-6alkyl-S—, —SO2N—R6R7, C6-14aryl-O-, heteroaryl-O—, —S((═O)5-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; or any one of R4 can be OH, C1-6alkoxy, —S—C1-6alkyl, COOR6, —NR6R7, —CONR6R7; or R4R4 may together be (═O); or R4R4together with the carbon to which they are attached may form a spiro ring of five to eight members optionally having 1-3 heteroatoms selected from N, O, S(═O), where n is 0-2, and N—R1; and
R6 and R7 are as defined in claim 1.

### Claim 3 (depends on 1, 2)

A compound according to claim 1, wherein A or B is a bicyclic heteroaryl group of the formula 1-B:
wherein:
Y1 and Y2 are independently C or N;
t is 1-4; and
Z1, Z2, Z3, W1, W2, W3, R1, R2, R4, R6, and R7 are as defined in claim 2.

### Claim 4 (depends on 2, 3)

A compound according to claim 3, wherein Z1, Z2, W1, and W2 are CR2, Z3 and Y1 are N, Y2, W3 is S; and
R1, R2, R4, R6, and R7 are as defined in claim 2.

### Claim 5 (depends on 4)

A compound according to claim 4 wherein R2 is H.

### Claim 6 (depends on 1, 3)

A compound according to claim 1, wherein A or B is a bicyclic heteroaryl group of the formula 1-C
wherein:
one of Z1, Z2, Z3 and Z4 is a carbon bonded to the remainder of the molecule and the other three are independently CR2 or N;
t is 1-4; and
W1, W2, W3, Y1, Y2, and R2 are as defined in claim 3.

### Claim 7 (depends on 2)

A compound according to claim 2 wherein one of Z1, Z2, or Z3 is CR2.

### Claim 8 (depends on 2)

A compound according to claim 2, wherein at least one of Z2 or Z3 is N, O, or S.

### Claim 9 (depends on 2)

A compound according to claim 2, wherein at least one of W1, W2, and W3 is CR4R4.

### Claim 10 (depends on 2)

A compound according to claim 2, wherein W1, W2, and W3 are all independently CR4R4.

### Claim 11 (depends on 2)

A compound according to claim 2, wherein t is 1-3.

### Claim 12 (depends on 3)

A compound according to claim 3, wherein t is 3.

### Claim 13 (depends on 3)

A compound according to claim 3, wherein at least two of Z1, Z2, Z3, Y1, and Y2 are N.

### Claim 14 (depends on 3)

A compound according to claim 3, wherein three of Z1, Z2, Z3, Y1, and Y2 are N.

### Claim 15 (depends on 3)

A compound according to claim 3, wherein two of W1, W2, and W3 are independently CR4R4.

### Claim 16 (depends on 15)

A compound according to claim 15, wherein each R4 is H.

### Claim 17 (depends on 3)

A compound according to claim 3, wherein one of Y1 and Y2 is CR2 and the other is N.

### Claim 18 (depends on 3)

A compound according to claim 3, wherein two of Z1, Z2, and Z3 are independently CR2.

### Claim 19 (depends on 6)

A compound according to claim 6, wherein at least three of Z1, Z2, Z3, and Z4 are independently CR2.

### Claim 20 (depends on 6)

A compound according to claim 6, wherein at least one of Z1, Z2, Z3, and Z4 is N.

### Claim 21 (depends on 20)

A compound according to claim 20, wherein Z1 is N.

### Claim 22 (depends on 6)

A compound according to claim 6, wherein at least two of Z1, Z2, Z3, and Z4 are N.

### Claim 23 (depends on 6)

A compound according to claim 6 wherein at least three of Z1, Z2, Z3, and Z4 are N.

### Claim 24 (depends on 1)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 2-A or 2-B
wherein:
one of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5, Z6 and Z7 are independently selected from CR2, N, O, S and N—R1, with the proviso that in formula 2-B, Z1, Z2, Z3, Z4, Z5 and Z6 are selected from CR2 and N;
Y1, Y2, Y3 and Y4 are each independently C or N;
R1 is H, —CONR6R7, —SO2NR6R7, or is a group selected from C1-6ealkyl, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C3-7cycloalkyl, C2-8alkenyl, C2-6alkynyl, C1-6perfluoroalkyl, —S(═O)2C1-6alkyl or C6-14aryl, —C(═O) heteroaryl, —C(═O)aryl, —C(═O)(C1-6alkyl), —C(═O)C3-6cycloalkyl, —C(═O) mono or bicyclic saturated heterocyclyl, C1-6alkylaryl, (C1-6alkyl)heteroaryl, aryl(C1-6alkyl), heteroaryl(C1-6alkyl), C1-6alkyl mono or bicyclic saturated heterocyclyl, arylalkenyl of 8 to 16 carbon atoms, arylalkyloxyalkyl, (C1-6alkyl )O(C1-6alkyl)-aryl, (C1-6alkyl )O(C1-6alkyl)heteroaryl, aryloxyalkyl, heteroaryloxyalkyl, aryloxyaryl, aryloxyheteroaryl, alkylaryloxyaryl, alkylaryloxyheteroaryl, alkylaryloxyalkylamines, C1-6alkoxycarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, said group being optionally substituted with nitro, -aryl, heteroaryl, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoro methyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; provided the atom of R1 which bonds to N is not a carbon that is double or triple bonded to another carbon.
R2 is absent, hydrogen, halogen, cyano, N—R6R7, hydroxy; COOR6, C1-6alkylamino (C1-6alkoxy), alkylenedioxy, C1-6perfluoroalkyl, CONR6R7, guanidino or cyclic guanidino, SO2NR6R7, C1-6alkyl, C2-8alkenyl having 1 to 2 double bonds, C2-6alkynyl having 1 to 2 triple bonds; C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxy, alkylaryloxy alkylamines, aryloxy, heteroaryloxy, alkenyloxy, alkynyloxy, aryloxyalkyl amine, C1-6perfluoroalkyl, S(═O)q—C1-6alkyl, S(═O)q where q is 0-2, alkylaryl, arylalkyl, C1-6alkylheteroaryl, heteroaryl-C1-6alkyl, C1-6alkyl mono or bicyclic saturated heterocyclyl having 1-3 heteroatoms independently selected from O, N or S, arylalkenyl of 8 to 16 carbon atoms, arylalkyloxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, aryloxyaryl, aryloxyheteroaryl, heteroaryloxyaryl, alkyl aryloxyaryl, alkylaryloxyhethoaryl, aryloxyalkyl, heteroaryloxyalkyl, alkylaryloxyalkylamines, C3-7cycloalkyl, saturated or partially saturated heterocyclyl, said group being optionally substituted with nitro, C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S,C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, C1-6alkyl-S—, —SO2N—R6R7, C6-14aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, -alkyl-aryl-O-alkylN—R5R7, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; provided that the atom of R2 that bonds to N is not a carbon that is double or triple bonded to another carbon;
R6 and R7 are independently H, or a group selected from C1-6alkyl, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, alkylaryl, arylalkyl, heteroarylalkyl, C1-6alkylheteroaryl, said group being optionally substituted with nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O-cyano, -halogen, -hydroxy, —NR6R7, —COOH, —COO-alkyl, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl, alkoxyalkyl-, C1-6alkyl-S-, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl, wherein s is 0-2, -alkyl-O-alkyl-NR6R7, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl, wherein s is 0-2, or R6 and R7 can together with the nitrogen to which they are attached form a 3 to 7 membered saturated ring system optionally having in addition to the N one or two heteroatoms selected from N—R1, O, and S(═O)n, where n is 0-2.

### Claim 25 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 3-A, 3-B, 4-A, 4-B, 5-A, 5-B, or 5-C
wherein:
one of Z1, Z2, Z3, Z4, Z5, Z6, Z7, and Z8 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5, Z6, Z7, and Z8 are independently selected from CR2, N, O, S, and N—R1; and Y1, Y2, Y3, Y4, R1, and R2 are as defined in claim 24.

### Claim 26 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 6-A or 6-B
wherein:
one of Z1, Z2, Z3, and Z4, is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, and Z4 are independently selected from CR2, N, O, S, and N—R1;
W1, W2, and W3 are each independently selected from CR4R4, S(═O)r where r is 0-2, O, and N—R1, with the proviso that whenever W2 is S or O it is not adjacent to a W1, W2 or W3 that is also S or O each R4 is independently H or C1-6alkyl optionally substituted with nitro, C6-14aryl, a 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, alkoxyalkyl-, C1-6alkyl-S—, —SO2N—R6R7, C6-14aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; or any one of R4 can be OH, C1-6alkoxy, COOR6, —NR6R7, —CONR6R7; or R4R4 may together be (═O); or R4R4 together with the carbon to which they are attached may form a spiro ring of five to eight members optionally having 1-3 heteroatoms selected from N, O, S(═O)n where n is 0-2, and N—R1;
t is 1-3; and
Y1, Y2, Y3, Y4, R1, R2, R6, and R7 are as defined in claim 24.

### Claim 27 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 7-A, 7-B, or 7-C
wherein:
one of Z1, Z2, Z3, Z4, and Z5, is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4 and Z5 are independently selected from CR2, N, O, S and N—R1;
t is 1-3; and
Y1, Y2, Y3, Y4, W1, W2, W3, R1, R2, R4, R6, and R7 are as defined in claim 24.

### Claim 28 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 8-A or 8-B
wherein:
one of Z1, Z2, Z3, Z4, Z5, and Z6 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5 and Z6 are independently selected from CR2, N, O, S, and N—R1;
t is 1-3; and
Y1, Y2, Y3, Y4, W1, W2, R1, R2, R4, R6, and R7 are as defined in claim 24.

### Claim 29 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 9-A or 9-B
wherein:
one of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5, Z6 and Z7 are independently selected from CR2, N, O, S, and N—R1;
t is 0-3; and
Y1, Y2, Y3, Y4, W1, W2, R1, R2, R4, R6, and R7 are as defined in claim 24.

### Claim 30 (depends on 1, 20, 24)

A compound according to claim 1 or 20, wherein A or B is a tricyclic heteroaryl group of the formula 10-A or 10-B
wherein:
one of Z1, Z2, and Z3 is a carbon bonded to the remainder of the molecule and the other Z1, Z2 and Z3 are independently selected from CR2, N, O, S, and N—R1;
Y1 and Y4 are independently C or N; Y2 and Y3 are independently CH or N; W1, W2, W3, W4, and W5 are independently selected from CR4R4, S(═O)r where r is 0-2, 0, and N—R1; with the proviso that whenever W2 is S or O it is not adjacent to a W1, W2 or W3 that is also S or O, with the proviso that whenever W2 is S or O it is not adjacent to a W1, W2 or W3 that is also S or O; t is 0-2; u is 1-3; and
R1, R2 and R4 are as defined in claim 24.

### Claim 31 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 11-A or 11-B
wherein
one of Z1, Z2, Z3, Z4, Z5, Z7, Z8 and Z9 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8 and Z9 are independently selected from CR2, N, O, S, and N—R1; and
Y1, Y2, Y3, Y4, R1 and R2 are as defined in claim 24.

### Claim 32 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 12-A, 12-B, or 12-C
wherein:
one of Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9 and Z10 is a carbon bonded to the remainder of the molecule and the other Z1Z2Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 are independently selected from CR2, N, O, S and N—R1; Y1, Y2, Y3, and Y4 are independently C or N; and R1 and R2 are as defined in claim 24.

### Claim 33 (depends on 1, 24)

A compound according to claim 1, wherein the tricyclic heteroaryl group has the formula 13-A or 13-B
wherein:
one of Z1, Z2, Z3, Z4, and Z5 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4 and Z5 are independently selected from CR2, N, O, S, and N—R1;
t is 1-4; and
Y1, Y2, Y3, Y4, W1, W2, W3, R1, R2, R4, R6, and R7 are as defined in claim 24.

### Claim 34 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 14-A, 14-B, or 14-C
wherein:
one of Z1, Z2, Z3, Z4, Z5, and Z6 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5, and Z6 are independently selected from CR2, N, O, S, and N—R1;
t is 1-3; and
Y1, Y2, Y3, Y4, W1, W2, W3, R1, R2, R4, R6, and R7 are as defined in claim 24.

### Claim 35 (depends on 1, 24)

A compound according to claim 1, wherein A or B is a tricyclic heteroaryl group of the formula 15-A, 15-B, or 15-C
wherein:
one of Z1, Z2, Z3, Z4, Z5, Z6, Z7, and Z5 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, Z4, Z5, Z6, Z7 and Z8 are independently selected from CR2, N, O, S, and N—R1;
t is 1-2; and
Y1, Y2, Y3, Y4, W1, W2, R1, R2, R4, R6, and R7 are as defined in claim 24.

### Claim 36 (depends on 1, 20, 28)

A compound according to claim 1 or 20 wherein the tricyclic heteroaryl group has the formula 16-A, 16-B, or 16-C
wherein:
one of Z1, Z2, Z3, and Z4 is a carbon bonded to the remainder of the molecule and the other Z1, Z2, Z3, and Z4 are independently selected from CR2, N, O, S, and N—R1;
t is 1-3;
u is 1-3; and
Y1, Y2, Y3, Y4, W4, W5, R1, R2, R4, R6, and R7 are as defined in claim 28.

### Claim 37 (depends on 1)

A compound of claim 1, wherein the compound is selected from:
(a) (5R), (6E)-6-(2,3-dihydro-imidazo[2,1-b]thiazol-5-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt;
(b) (5R), (6E)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(c) (5R), (6E)-6-(7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(d) (5R), (6E)-7-oxo-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(e) (5R), (6E)-6-{[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(f) (5R), (6E)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(g) (5R), (6E)-6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(h) (5R), (6E)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(i) (5R), (6E)-6-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(j) (5R), (6E)-7-oxo-6-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-ylmethylene)-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(k) (5R), (6E)-6-(7-methyl-6-oxo-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt; or
(l) (5R), (6E)-6-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazin-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(m) (5R), (6E)-7-Oxo-6-(4H-5-thia-1,6a-diazapentalen-2-ylmethylene)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(n) (5R), (6E)-6-(7H-imidazo[1,2-c]thiazol-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(o) (5R), (6E)-7-oxo-6-[(4-oxo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)methylene]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(p) 6-(6,7-dihydro-4H-thieno[3,2-c]pyran-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(q) 6-(6,7-dihydro-4H-thieno[3,2-c]thiopyran-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(r) 6-(5-methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(s) 2-(2-Carboxy-7-oxo-1-aza-bicyclo[3.2.0]hept-2-en-6-ylidenemethyl)-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylic acid ethyl ester; or
(t) 7-oxo-6-(6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-2-ylmethylene)-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(u) (5R), (6E)-6-(7-benzyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(v) (5R), (6E)-7-oxo-6-{[5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(w) (5R), (6E)-7-oxo-6-{[5-(pyridin-3-ylcarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]methylene}-7oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(x) (5R), (6E)-7-oxo-6-{[5-(phenylacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]methylene}-7oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(y) (5R), (6E)-6-(6,7-dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(z) (5R), (6E)-7-oxo-6-(5,6,7,8-tetrahydroimidazo[2,1-b][1,3]benzothiazol-2-ylmethylene)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt; or
(aa) (5R), (6E)-6-(5,8-dihydro-6H-imidazo[2,1-b]pyrano[4,3-d][1,3]thiazol-2-ylmethylene)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(bb) (5R), (6E)-6-(4,5,6,7-tetrahydro-1,3a,3b,8-tetraaza-cyclopenta[a]indene-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt;
(cc) (5R), (6E)-6-(5H-imidazo[2,1-a]isoindol-2-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt; or
(dd) (5R), (6E)-7-oxo-6-(5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]benzoxazol-2-ylmethylene)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(ee) (5R), (6E)-6-(7,8-dihydro-5H-pyrano[4,3-d]pyrazolo[5,1-b][1,3]oxazol-2-ylmethylene)7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(ff) (5R), (6E)-6-{[6-(ethoxycarbonyI)-5,6,7,8-tetrahydropyrazolo[5′,1′,2,3][1,3]oxazolo[5,4-c]pyridin-2-yl]methylene}-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(gg) (5R), (6E)-6-({5-[2-(benzyloxy)ethoxy]-7,8-dihydro-6H-cyclopenta[e]imidazo[1,2-a]pyrimidin-2-yl}methylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(hh) (5R), (6E)-6-[(5-methoxy-7,8-dihydro-6H-cyclopenta[e]imidazo[1,2-a]pyrimidin-2-yl)methylene]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(ii) (5R), (6E)-6-imidazo[1,2-a]quinolin-2-ylmethylene-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(jj) (5R), (6E)-6-(imidazo[1.2-a]quinoxaline-2-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hepto-2-ene-2-carboxylic acid, sodium salt; or
(kk) (5R), (6E)-6-(imidazo[2,1-b]benzothiazol-7-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(ll) (5R), (6E)-6-(2,3-dihydro[1,3]thiazolo[3,2-a]benzimidazol-6-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(mm)(5R), (6E)-7-oxo-6-([1,3]thiazolo[3,2-a]benzimidazol-6-ylmethylene)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(nn) (5R), (6E)-6-(3,4-dihydro-2H-[1,3]thiazino[3,2-a]benzimidazol-7-ylmethylene)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(oo) (5R), (6E)-7-oxo-6-([1,3]thiazolo[3,2-a]benzimidazol-2-ylmethylene)-1-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(pp) (5R), (6E)-7-oxo-6-(4H-thieno[2′,3′,4,5]thiopyrano[2,3-b]pyridin-2-ylmethylene)-1-azabicyclo[3.2,0]hept-2-ene-2-carboxylic acid, sodium salt; or
(qq) (5R), (6E)-8-[(9-methyl-9H-imidazo[1,2-a]benzimidazol-2-yl)methylene]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt; or
(rr) (5R), (6E)-6-(7,8-dihydro-5H-pyrano[4,3-d]pyrazolo[5,1-b][1,3]oxazol-2-ylmethylene)7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(ss) 6-(5-ethoxy-7,8-dihydro-6H-3,4,8b-triaza-as-indacen-2-ylmethylene)-7-oxo -1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; or
(tt) (5R), (6E)-6-(7,8-dihydro-5H-pyrano[4,3-d]pyrazolo[5,1-b][1,3]oxazol-2-ylmethylene)7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt and (5R), (6E)-6-(7,8-dihydro-5H-pyrano[4,3-d]pyrazolo[5,1-b][1,3]oxazol-2-ylmethylene)7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt; or
(uu) (5R), (6E)-6-{[6-(ethoxycarbonyl)-5,6,7,8-tetrahydropyrazolo [5′,1′:2, 3][1, 3}oxazolo [5,4-c]pyridin-2-yl]methylene}-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt.

### Claim 38 (depends on 37)

A compound of claim 37, wherein the compound is (5R), (6E)-6-(2,3-dihydro-imidazo[2,1-b]thiazol-5-ylmethylene)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid, sodium salt.

### Claim 39

A method for treating a bacterial infection or disease comprising providing to a patient in need thereof an effective amount of cefepime or a pharmaceutically acceptable salt thereof and compound of formula I
wherein:
one of A and B denotes hydrogen and the other an 8- to 14-membered fused bicyclic or tricyclic heteroaryl group optionally substituted with nitro, C6-14aryl, -heteroaryl, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, -N—R6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, —SO2NHR6, —CO2H, CONR6R7, aryl-O—, heteroaryl-O—, —S(═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, Cmalkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N—(C1-6alkyl), and —S(═O)s-heteroaryl where s is 0-2;
R5 is H, C1-6alkyl, C5-6cycloalkyl, or CHR3OCOC1-6alkyl;
R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C6-14aryl, or 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, wherein aryl or heteroaryl can be optionally substituted with 1 or 2 of nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN-R6R7, -alkyl-aryl-O-alkylN—R5R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; and
R6 and R7 are independently H, or a group selected from C1-6alkyl, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, alkylaryl, arylalkyl, heteroarylalkyl, C1-6alkylheteroaryl, said group being optionally substituted with nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O-cyano, -halogen, -hydroxy, —NR6R7, —COON, —COO-alkyl, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl, alkoxyalkyl-, C1-6alkyl-S—, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl, wherein s is 0-2, -alkyl-NR6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)5-heteroaryl, wherein S is 0-2, or R6 and R7 can together with the nitrogen to which they are attached form a 3 to 7 membered saturated ring system optionally having one or two heteroatoms selected from N—R1, O, and S(═O)n, where n is 0-2;
or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein A or B is a bicyclic heteroaryl group of the formula II

### Claim 41 (depends on 39)

The method of claim 39, comprising co-administering cefepime or a pharmaceutically acceptable salt thereof and the compound of formula I or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein the ratio of cefepime or a pharmaceutically acceptable salt thereof to the compound of formula I or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof is from about 1:1 to about 100:1.

### Claim 43 (depends on 42)

The method of claim 42, wherein the ratio of cefepime or a pharmaceutically acceptable salt thereof to the compound of formula I or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof is less than about 10:1.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The method of any one of claims 39-43, comprising orally administering to a patient.

### Claim 45 (depends on 39, 40, 41, 42, 43)

The method of any one of claims 39-43, comprising intravenously administering to a patient.

### Claim 46

A composition comprising a pharmaceutically acceptable carrier, cefepime or a pharmaceutically acceptable salt thereof, and a compound of formula I
wherein:
one of A and B denotes hydrogen and the other an 8- to 14-membered fused bicyclic or tricyclic heteroaryl group optionally substituted with nitro, -aryl, -heteroaryl, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O-C2-4alkyl-O—, -cyano, -halogen, -hydroxy, -N—R6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, —SO2NHR6, —CO2H, CONR6R7, aryl-O—, heteroaryl-O—, —S(═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N—(C1-6alkyl), and -S(═O)s-heteroaryl where s is 0-2;
R5 is H, C1-6alkyl, C5-6cycloalkyl, or CHR3OCOC1-6alkyl; and
R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C6-14aryl, or heteroaryl, wherein aryl or heteroaryl can be optionally substituted with 1 or 2 of nitro, -aryl, -heteroaryl, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, -aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2; or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 46)

The composition of claim 46, wherein the bicyclic heteroaryl group has the formula II:

### Claim 48 (depends on 46)

The composition of claim 46, wherein the ratio of cefepime or a pharmaceutically acceptable salt thereof to the compound of formula I or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof is from about 1:1 to about 100:1.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the ratio of cefepime or a pharmaceutically acceptable salt thereof to the compound of formula I or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof is less than about 10:1.

### Claim 50 (depends on 1)

A process for preparing a compound of formula I as claimed in claim 1, which comprises subjecting to reductive elimination a compound of formula III:
wherein A′ is A or B as defined in claim 1, P is an ester leaving group, R is a protecting group that can be removed to give a compound of formula I
or a pharmaceutically acceptable salt or ester thereof.

### Claim 51 (depends on 50)

The process according to claim 50, wherein the ester leaving group is selected from O-acetate, O-mesylate, O-triflate, O-tosylate, and tosylate.

### Claim 52 (depends on 50, 51)

The process according to claim 50 or 51, wherein the protecting group is a para-nitrobenzyl group.
